Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC)

NCT01805908 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Accrual is very poor

Conditions

Breast Cancer

Interventions

OTHER: 111In-Pertuzumab + SPECT-CT

Sponsor

Ontario Clinical Oncology Group (OCOG)